Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects

Joffe, Preben; Larsen, Frank; Pedersen, V.; Ring‐Larsen, Helmer; Aaes‐Jørgensen, T.; Sidhu, J.

doi:10.1007/s002280050452

Cited by 56 publications

(42 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…55 Ritonavir, a potent CYP3A4 inhibitor, showed no effect on escitalopram pharmacokinetics. 53 In contrast, cimetidine and omeprazole increased escitalopram exposure, but the effect is probably not of clinical concern.…”

Section: (Continued)mentioning

confidence: 99%

“…48,49 The process is not affected by food. 55 The pharmacokinetic profiles of the newer antidepressants are summarized in Table 2 73,75 Possibly more effective than duloxetine, fluoxetine, fluvoxamine, paroxetine, and reboxetine 77 Escitalopram may be suitable in moderate to severe major depression and in adolescents. Nausea (15%), insomnia (9%), sexual dysfunction (9%), diarrhea (8%), dry mouth (6%) agitation/restlessness, daytime sedation.…”

Section: Escitaloprammentioning

confidence: 99%

“…54 Concomitant administration of escitalopram with MAOIs or other SSRIs should be avoided because of possible serotonin syndrome. 55 The elimination half-life is relatively short compared with other SSRIs, and steady-state plasma concentrations are achieved in a week. 56 The main elimination route is renal.…”

Section: (Continued)mentioning

confidence: 99%

“…55 Escitalopram shows linear and dose-proportional pharmacokinetics in the dose range 10-30 mg/day. 55,56 No reduction of citalopram dosage seems to be necessary in patients with moderately impaired renal function, but may be appropriate in patients with impaired hepatic function. 55 Age and gender showed no clinically significant influence on escitalopram pharmacokinetics.…”

Section: (Continued)mentioning

confidence: 99%

“…Perović et al Escitalopram is extensively metabolized in the liver via oxidative metabolism. 50,55 In the brain, metabolism of escitalopram propionate may be mediated by MAO-A, MAO-B, and aldehyde oxidase. 51,52 Nevertheless, the metabolites do not contribute appreciably to therapeutic activity.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Getting the balance right: Established and emerging therapies for major depressive disorders

Perović

Jovanović²,

Miljković³

et al. 2010

NDT

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.

show abstract

Section: (Continued)mentioning

confidence: 99%